Astellas Pharma Inc. and Vir Biotechnology announced a global strategic collaboration to accelerate the development of the investigational prostate cancer therapy VIR-5500. This PSMA?targeting PRO XTEN® dual?masked T?cell engager aims to improve outcomes for patients with aggressive disease. By combining scientific expertise and commercial strength, the partnership seeks to advance this novel immuno-oncology candidate and transform care for men with advanced metastatic prostate cancer.
Under the collaboration, Astellas and Vir Biotechnology will share development responsibilities and costs. Astellas will lead the commercialization of PSMA?targeting PRO XTEN® VIR-5500 in the United States and retain exclusive marketing rights outside the U.S. Vir has the option to co-promote in the U.S. market. In addition, Vir will receive $335 million in upfront and near-term milestone payments and could earn up to $1.37 billion in further development, regulatory, and sales milestones, along with tiered double-digit royalties on ex-U.S. net sales.
Adam Pearson, Astellas’ Chief Strategy Officer, said the company’s experience in prostate cancer and immuno-oncology allows rapid advancement of VIR-5500. Marianne De Backer, CEO of Vir Biotechnology, emphasized that the collaboration demonstrates strong confidence in the PRO XTEN® platform. She added that it has the potential to deliver safer, more effective treatments for solid tumors.
Despite progress in prostate cancer management, metastatic castration-resistant prostate cancer remains difficult to treat. Limited therapeutic options persist, and the five-year survival rate remains near 30%. PSMA?targeting PRO XTEN® VIR-5500 aims to activate the body’s T cells against cancer cells while minimizing off-target toxicity. Its dual-masked design keeps the T?cell engager inactive until it reaches the tumor microenvironment. This potentially improves the therapeutic index compared with conventional T-cell engagers.
The growth is attributed to the rising R&D activities undertaken to introduce new drug compounds for prostate cancer treatment. Prostate-specific membrane antigen (PSMA), highly expressed in prostate cancer cells, has become a key therapeutic target. Lutetium-177-PSMA-617 (Pluvicto) exemplifies this approach, showing promising results in clinical trials for metastatic castration-resistant prostate cancer (mCRPC). By binding specifically to PSMA, it delivers targeted radiation to cancer cells, improving survival rates compared with traditional therapies.
VIR-5500 is currently in an ongoing Phase 1 clinical trial for patients with advanced metastatic prostate cancer who have progressed after multiple therapies. Updated data indicate a favorable safety profile and strong dose-dependent anti-tumor activity, including high rates of prostate-specific antigen (PSA) reductions. These findings will be presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. It is reinforcing the candidate’s potential as a differentiated immuno-oncology therapy.
The collaboration strengthens Vir Biotechnology’s financial position while sharing development risk. This support allows Vir to expand its oncology portfolio. Astellas leverages its global infrastructure to accelerate access to VIR-5500 for patients upon regulatory approval and successful development.
Industry analysts view the partnership as a significant step. It combines Vir’s cutting-edge PRO XTEN® technology with Astellas’ commercialization capabilities. The dual-masked PSMA?targeting PRO XTEN® design could reduce toxicities typically seen with T-cell engagers in solid tumors, potentially allowing outpatient treatment and improving patients’ quality of life.
Financial experts note that upfront and milestone payments highlight the high unmet need in metastatic prostate cancer. These investments demonstrate confidence in PRO XTEN® -enabled T-cell engagers. While U.S. profits and losses are shared equally, Astellas handles commercialization outside the United States, supporting broad global access.
The alliance shares development costs, with Astellas covering 60% and Vir 40%. This arrangement allows rapid responses to clinical data and efficient trial advancement. Vir’s U.S. co-promotion option ensures continued involvement in commercial execution and patient engagement.
Looking ahead, both companies plan to initiate registrational trials for PSMA targeting PRO XTEN® VIR-5500 in 2027, pending regulatory alignment and successful development. If these trials confirm early promising results, VIR-5500 could become one of the first effective T-cell engagers for advanced prostate cancer, reshaping treatment options and offering hope to patients with limited alternatives.
Overall, the strategic collaboration between Astellas and Vir Biotechnology marks a significant milestone in prostate cancer therapy. The PSMA?targeting PRO XTEN® T-cell engager VIR-5500 combines scientific innovation with global development and commercial expertise, poised to transform oncology.
